Haoran Zha et al. (82) used MX53 (a C5aR antagonist) to pharmacologically block C5aR signaling in mice tumor model and also observed a greatly enhance of anti-PD-1/PD-L1 efficacy (82). Here, PDCD1 is linked to neoplasm.